Skip to main content

LifeStance Health Group, Inc. (LFST) Stock Analysis

SellVALUE-TRAP 2/5Moderate Confidence

Healthcare · Medical Care Facilities

Earnings in 7 days (2026-05-07). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Sell if holding. At $7.47, A.R:R 0.9:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Customer: UnitedHealthcare (14.0%); Concentration risk — Customer: Elevance Health, Inc. (15.0%).

LifeStance Health operates one of the largest outpatient mental health platforms in the U.S., with 8,040 licensed clinicians in 33 states offering psychiatric, psychological, and therapy services in-person and virtually. Revenue is generated primarily through in-network... Read more

$7.47+14.1% A.UpsideScore 5.3/10#15 of 27 Medical Care Facilities
Stop $7.04Target $8.55(analyst − 13%)A.R:R 0.9:1
Analyst target$9.83+31.6%9 analysts
$8.55our TP
$7.47price
$9.83mean
$12

Sell if holding. At $7.47, A.R:R 0.9:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Customer: UnitedHealthcare (14.0%); Concentration risk — Customer: Elevance Health, Inc. (15.0%). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.3/10, moderate confidence.

Passes 5/7 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on favorable risk/reward ratio and earnings proximity 7d<=7d. Suitability: aggressive.

Thesis

Rewards
No bull case signals
Risks
Concentration risk — Customer: UnitedHealthcare (14.0%)
Concentration risk — Customer: Elevance Health, Inc. (15.0%)
Earnings in 7 days (event risk)

Key Metrics

P/E (TTM)371.5
P/E (Fwd)19.4
Mkt Cap$2.9B
EV/EBITDA39.1
Profit Mgn0.7%
ROE0.7%
Rev Growth17.4%
Beta1.13
DividendNone
Rating analysts17

Quality Signals

Piotroski F9/9

Options Flow

P/C4.60bearish
IV90%elevated
Max Pain$1-86.6% vs spot

Concentration Risks(10-K Item 1A)

  • HIGHCustomerUnitedHealthcare14%
    10-K Item 1A: 'Two payors individually exceeded 10% of our total revenue for the year ended December 31, 2025: UnitedHealthcare and Elevance Health, Inc., comprising 14% and 15% of our total revenue'
  • HIGHCustomerElevance Health, Inc.15%
    10-K Item 1A: 'Two payors individually exceeded 10% of our total revenue for the year ended December 31, 2025: UnitedHealthcare and Elevance Health, Inc., comprising 14% and 15% of our total revenue'

Material Events(8-K, last 90d)

  • 2026-03-11Item 5.02LOW
    Lisa Miller promoted to Chief Operating Officer and Principal Operating Officer effective March 10, 2026. Previously EVP Practice Operations. No departure of prior COO cited.
    SEC filing →
  • 2026-02-25Item 5.02LOW
    Kenneth Burdick transitions from Executive Chairman to non-executive Chairman effective March 16, 2026. Will receive standard non-employee director compensation. Not due to disagreement.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

2 floor-breakers

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Value Rank
0.4
Quality Rank
0.8
Growth Rank
7.3

Technicals below the gate floor. Component breakdown shows what dragged the score down.static

Bollinger
0.8
Support Resistance
1.8
52w Position
8.5
GatesA.R:R 0.9 < 1.5@spotEARNINGS PROXIMITY 7d<=7dMomentum 6.3>=5.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTSEMI CYCLE PEAK CLEARSuitability: Aggressive
RSI
80 · Overbought
20D MA 50D MA 200D MAGOLDEN CROSSSupport $6.21Resistance $7.77

Price Targets

$7
$9
A.Upside+14.5%
A.R:R0.9:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Reward/Risk 0.9:1 at current price — below 1.5:1 minimum
! EARNINGS_PROXIMITY:7d<=7d

Earnings

B
B
M
M
2/4 beats
Next Earnings2026-05-07 (7d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is LFST stock a buy right now?

Sell if holding. At $7.47, A.R:R 0.9:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Customer: UnitedHealthcare (14.0%); Concentration risk — Customer: Elevance Health, Inc. (15.0%). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $7.04. Score 5.3/10, moderate confidence.

What is the LFST stock price target?

Take-profit target: $8.55 (+14.1% upside). Prior stop was $7.04. Stop-loss: $7.04.

What are the risks of investing in LFST?

Concentration risk — Customer: UnitedHealthcare (14.0%); Concentration risk — Customer: Elevance Health, Inc. (15.0%); Earnings in 7 days (event risk).

Is LFST overvalued or undervalued?

LifeStance Health Group, Inc. trades at a P/E of 371.5 (forward 19.4). TrendMatrix value score: 6.3/10. Verdict: Sell.

What do analysts say about LFST?

17 analysts cover LFST with a consensus score of 4.1/5. Average price target: $10.

What does LifeStance Health Group, Inc. do?LifeStance Health operates one of the largest outpatient mental health platforms in the U.S., with 8,040 licensed...

LifeStance Health operates one of the largest outpatient mental health platforms in the U.S., with 8,040 licensed clinicians in 33 states offering psychiatric, psychological, and therapy services in-person and virtually. Revenue is generated primarily through in-network insurance reimbursements, with 95% of patients insured as of their latest visit in 2025. Two payors, UnitedHealthcare (14%) and Elevance Health (15%), each exceeded 10% of total revenue.

Related stocks: UHS (Universal Health Services, Inc.) · AVAH (Aveanna Healthcare Holdings Inc) · ADUS (Addus HomeCare Corporation) · ASTH (Astrana Health Inc.) · CON (Concentra Group Holdings Parent)